Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to “Hold”

ImageneBio (NASDAQ:IMA) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Wedbush downgraded ImageneBio from a “neutral” rating to an “underperform” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $26.50.

ImageneBio Price Performance

NASDAQ IMA opened at $5.91 on Friday. ImageneBio has a 12 month low of $5.70 and a 12 month high of $18.00. The firm has a market capitalization of $66.07 million, a PE ratio of -0.73 and a beta of 0.44. The company’s 50 day simple moving average is $6.72 and its 200 day simple moving average is $7.58.

ImageneBio (NASDAQ:IMA) last released its earnings results on Tuesday, March 10th. The company reported $0.34 earnings per share for the quarter. Sell-side analysts anticipate that ImageneBio will post -0.91 earnings per share for the current fiscal year.

Insider Activity at ImageneBio

In other ImageneBio news, Director Joseph P. Slattery bought 16,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The shares were acquired at an average cost of $5.99 per share, for a total transaction of $95,840.00. Following the acquisition, the director directly owned 16,000 shares of the company’s stock, valued at $95,840. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 5.94% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMA. Barclays PLC increased its holdings in shares of ImageneBio by 170.8% in the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after buying an additional 6,810 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of ImageneBio during the 4th quarter worth $76,000. Millennium Management LLC acquired a new position in shares of ImageneBio in the 4th quarter worth $79,000. T3 Companies LLC acquired a new stake in shares of ImageneBio during the fourth quarter worth $91,000. Finally, Jane Street Group LLC acquired a new stake in shares of ImageneBio during the fourth quarter worth $103,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.